We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+36.64%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.35B
AUM Growth
+$446M
Cap. Flow
+$266M
Cap. Flow %
19.74%
Top 10 Hldgs %
44.95%
Holding
104
New
31
Increased
29
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$40.1M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$34.3M
3
ONC
BeOne Medicines Ltd
ONC
+$23.8M
4
BIIB icon
Biogen
BIIB
+$17M
5
KROS icon
Keros Therapeutics
KROS
+$16.2M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$46.4M
2
GSK icon
GSK
GSK
+$39.6M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$26.2M
4
MREO
Mereo BioPharma
MREO
+$24.2M
5
VKTX icon
Viking Therapeutics
VKTX
+$16.4M

Sector Composition

Rank Sector Weight
1 Healthcare 84.45%
2 Consumer Staples 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EOLS icon
76
Evolus
EOLS
$501M
$2.24M 0.17%
+160,000
New +$2.08M
ARQT icon
77
Arcutis Biotherapeutics
ARQT
$3.18B
$2.23M 0.17%
+225,000
New +$1.68M
ANNX icon
78
Annexon
ANNX
$885M
$2.1M 0.16%
292,400
-223,000
-43% -$1.16M
APGE icon
79
Apogee Therapeutics
APGE
$10.2B
$1.33M 0.1%
20,000
-15,000
-43% -$655K
TMDX icon
80
Transmedics
TMDX
$2.91B
$1.23M 0.09%
16,700
-106,412
-86% -$8.77M
RCEL icon
81
Avita Medical
RCEL
$240M
$1.2M 0.09%
75,000
– –
PTGX icon
82
Protagonist Therapeutics
PTGX
$9.45B
$998K 0.07%
34,500
-48,500
-58% -$1.32M
DNLI icon
83
Denali Therapeutics
DNLI
$3.94B
$964K 0.07%
47,000
-83,000
-64% -$1.56M
CVRX icon
84
CVRx
CVRX
$62.6M
$883K 0.07%
+48,500
New +$1.15M
SKIN icon
85
SkinHealth Systems
SKIN
$85.7M
$755K 0.06%
170,000
+15,000
+10% +$48.7K
FOLD
86
DELISTED
Amicus Therapeutics
FOLD
$683K 0.05%
+57,966
New +$741K
TNYA icon
87
Tenaya Therapeutics
TNYA
$163M
$639K 0.05%
+122,222
New +$585K
SILK
88
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$183K 0.01%
10,000
-527,000
-98% -$8.36M
URGN icon
89
UroGen Pharma
URGN
$2.29B
$150K 0.01%
+10,000
New +$163K
LQDA icon
90
Liquidia Corp
LQDA
$8.02B
$148K 0.01%
10,000
– –
XERS icon
91
Xeris Biopharma Holdings
XERS
$1.37B
$137K 0.01%
62,083
– –
ABBV icon
92
AbbVie
ABBV
$434B
– –
-14,800
Closed -$2.29M
ADVM
93
DELISTED
Adverum Biotechnologies
ADVM
– –
-42,500
Closed -$320K
ATRC icon
94
AtriCure
ATRC
$2.11B
– –
-392,195
Closed -$14M
CVS icon
95
CVS Health
CVS
$122B
– –
-59,500
Closed -$4.7M
HOLX
96
DELISTED
Hologic
HOLX
– –
-34,000
Closed -$2.43M
ILMN icon
97
Illumina
ILMN
$28.4B
– –
-5,448
Closed -$738K
SIBN icon
98
SI-BONE Inc
SIBN
$835M
– –
-341,818
Closed -$7.17M
SNN icon
99
Smith & Nephew
SNN
$12.6B
– –
-470,198
Closed -$12.8M
YARW
100
Yarrow Bioscience, Inc. Common Stock
YARW
$112M
– –
-14,077
Closed -$1.64M
1 2 3
4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Soleus Capital Management held 104 positions worth $1.35B, up 50% from $901M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Soleus Capital Management deployed $266M of net new capital in Q1 2024, opening 31 new positions and adding to 29 existing holdings. Its largest new stake was BeOne Medicines Ltd: 148,100 shares worth $23.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 100% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was GSK, an estimated $39.6M trimmed.

  • Soleus Capital Management's largest Q1 2024 buy was BeOne Medicines Ltd: 148,100 shares worth $23.2M.
  • Soleus Capital Management added most to TG Therapeutics in Q1 2024, an estimated $40.1M increase.
  • Soleus Capital Management's biggest Q1 2024 reduction was GSK, cutting an estimated $39.6M.
  • Soleus Capital Management fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $46.4M.
  • Soleus Capital Management's ten largest holdings make up 45% of its $1.35B portfolio in Q1 2024.
  • Soleus Capital Management opened 31 new positions and closed 13 in Q1 2024.
  • Soleus Capital Management's portfolio value rose 50% quarter-over-quarter to $1.35B.

Based on Soleus Capital Management's 13F filing for Q1 2024, filed 15 May 2024.